Verzenio Is Significant– Cuts The Risk of Cancer Coming Back In Some Women With Early Breast Cancer– A First For CDK4/6 Inhibitors

Updated June 29th, 2020

Verzenio Is Significant– Cuts The Risk of Cancer Coming Back In Some Women With Early Breast Cancer– A First For CDK4/6 Inhibitors

During a clinical trial, researchers found that CDK4/CDK6 inhibitor Verzenio may have a huge impact on women battling early stage breast cancer by decreasing the likelihood of the cancer returning.

NOW
PLAYING
FDA Approves Combination of Keytruda & Lenvima For Treatment Of Advanced Uterine Cancer: What Women Need To Know
NOW
PLAYING
Does Tattoo Ink Impact Breast Cancer Screenings?
NOW
PLAYING
Jillian Barberie Gets Breast Cancer Screening After Double Mastectomy
NOW
PLAYING
Can an electronic nose sniff out cancer?
NOW
PLAYING
4 Major Cancer Treatment Advances Happened This Week. Here's What You Missed.
NOW
PLAYING
Major Advance: PARP Inhibitors Extend Life For Women With High Risk Breast Cancer & BRCA Mutations

Treatment: Lymphedema

SEE MORE   

Treatment: Lymphedema

Lymphedema is a chronic swelling that can occur after breast cancer surgery and radiation.

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.